Brivudine

SKU: orb1310353

Description

Brivudine (BVDU) is a nucleoside analogue antiviral agent utilized in research for the treatment of herpes zoster. It demonstrates potent in vitro activity against varicella-zoster virus (VZV) and has been evaluated in clinical studies for its therapeutic efficacy in vivo.

Research Area

Infectious Disease & Virology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 69304-47-8
• MW: 333.14
• Purity: 99.27% (May vary between batches)
• Formula: C₁₁H₁₃BrN₂O₅
• SMILES: OC[C@H]1O[C@H](C[C@@H]1O)n1cc(\C=C\Br)c(=O)[nH]c1=O
• Target: HSV,Virus Protease
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:10 mg/mL (30.02 mM);DMSO:50 mg/mL (150.09 mM)

Bioactivity

• In Vivo:
  At a dose of 125 mg once daily, brivudine has been shown to be superior to aciclovir with respect to reducing the period of new blister production and shortening the duration of post-herpetic neuralgia.
• In Vitro:
  Brivudine is an analog of thymidine, and is incorporated into the viral DNA. It blocks the action of DNA polymerases thereby inhibiting viral replication. It has a stronger antiviral effect against the varicella-zoster virus than reference compounds such as aciclovir or penciclovir. It has high, selective activity against varicella zoster virus (VZV), inhibiting VZV replication, possibly through competitive inhibition of viral DNA polymerase, or by acting as an alternative substrate to deoxythymidine triphosphate, causing viral DNA strand breakage.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CMV, Brivudine, Cytomegalovirus, Bromovinyldeoxyuridine, BVDU, HSV-1, Inhibitor, inhibit, VZV

Compound Identifiers

PubChem CID

446727